That is part of the problem. The other issue has been that in India they have not faced patents, so they were able to go ahead and make a product. And again, you've heard the difficulties that Apotex had in getting through the regulatory and legal requirements in Canada. They don't have any of those issues in India. Yes, cost is an issue, but so also are the legal difficulties.
Earlier someone mentioned the manufacturing capacity in Canada. Apotex itself--and if Jack wants to speak to this, he can--has more capacity to manufacture medicines in Canada than all of the brand-name industry combined in Canada. We have about eight or nine companies that have major manufacturing facilities on the generic side. That is why Canada wanted to have this legislation, because we do have a robust generic drug industry.